<DOC>
	<DOCNO>NCT02906995</DOCNO>
	<brief_summary>The purpose study compare two different dosage form nicotine release absorbed bloodstream .</brief_summary>
	<brief_title>Pharmacokinetics Nicotine Sublingual Tablets Versus Nicorette Lozenge Healthy Smokers</brief_title>
	<detailed_description>Objective The primary objective study determine pharmacokinetic profile single dose Nicotine Sublingual Tablets , 4 mg ( Test Product ) versus Nicorette Lozenge 4 mg healthy adult smoker administer fasted condition . Study Design This open-label , pseudorandomized , two-way crossover comparison 4 mg sublingual nicotine tablet versus Nicorette Lozenge 4 mg . Number Subjects Twenty-four ( 24 ) healthy adult smoker enrol . Screening Procedures Demographic data , medical medication history , physical examination , measurement height weight , electrocardiogram ( ECG ) , vital sign ( blood pressure , heart rate , body temperature respiratory rate ) , hematology , chemistry , urinalysis , end-expired Carbon Monoxide , serum pregnancy test ( female subject ) . Confinements Subjects confine approximately 2 hour earlier prior study drug administration discharge vital sign 240 minute ( min ) post-dose blood draw End-of-Study ( EOS ) procedure . Study Drug Administration A single dose Test Product ( Nicotine Sublingual Tablets , 4 mg ) Nicorette Lozenge 4 mg administer subject study . Sample Collection A total 14 blood sample obtain per period . Samples take pre-dose ( 90 minute prior dose ) 3 , 6 , 9 , 12 , 15 , 20 30 , 45 , 60 , 90 , 120 , 180 240 minute post-dose . A minimum 48 hour transpire dose administration . Safety Assessments Vital sign ( blood pressure , heart rate , body temperature respiratory rate ) measure administration study drug . The follow perform check-in : urine pregnancy test ( female subject ) . Ongoing monitor adverse event ( AEs ) perform study . Prior release clinic , well-being assessment discharge vital sign complete 240 minute ( ±60 min ) post dose Early Termination ( ET ) . End Study ( EOS ) Early Termination ( ET ) Procedures Vital sign monitor AEs do 240 min post-dosing ET/withdrawal prior release clinic . Analytical Method Plasma concentration nicotine determine use validated liquid chromatography-mass spectrometry/mass spectrometry ( LC-MS/MS ) method . Pharmacokinetics/Pharmacodynamics Determination primary parameter Area curve ( AUC0-t , AUC0-inf ) , concentration maximum ( Cmax ) , Time maximum concentration ( Tmax ) secondary parameter plasma elimination half-life ( t1/2 ) use non-linear kinetics program ( WinNonlin® ) . Pharmacodynamics effect measure take heart rate blood pressure take three time first 30 minute test product administration . A craving assessment obtain 1 , 3 , 7 , 11 , 14 minute post-medication administration . Statistical Analyses No formal statistical analysis plan ; descriptive statistic concentration pharmacokinetic data nicotine provide . Exploratory analysis crave reduction conduct .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>1 . Participants 1845 year old 2 . Participants must provide write informed consent prior study related procedure perform . 3 . Participants must willingness ability comply protocol requirement . 4 . Participants must good health free clinically significant pathology ( gastrointestinal tract , hepatic , renal , cardiovascular , CNS diseases ) 5 . Female participant childbearing potential , addition negative urine pregnancy test , must willing use form birth control study . The hormonal contraceptive avoid within 2 month prior study entry . 6 . Participants must consume 10 cigarette daily Fagerström Test Nicotine Dependence score 4 great . 7 . Participants must intention quit smoke next 60 day . 1 . Volunteers use nicotine delivery system nicotine lozenge , nicotine patch , nicotine inhaler , nicotine nasal spray etc within 30 day study entry . 2 . Volunteers currently involve another clinical trial use investigational drug within 3 month study entry . 3 . Volunteers pregnant lactating , plan become pregnant within 6 month . 4 . Volunteers diagnose heart disease treat medication irregular heartbeat myocardial infarction . 5 . Volunteers diagnose stomach ulcer . 6 . Volunteers take insulin diabetes . 7 . Volunteers high blood pressure control medication blood pressure great 150 mmHg systolic 90 mmHg diastolic . 8 . Volunteers unable fulfill visit schedule 9 . Volunteers severe allergic history 10 . Volunteers know intolerance medication 11 . Volunteers diagnose chronic disease cardiovascular , pulmonary , neuroendocrine system , gastrointestinal , hepatic , renal , blood disease 12 . Volunteers surgical operation gastrointestinal tract exception appendectomy 13 . Volunteers donate 450 mL his/her blood blood plasma within last 2 month prior study entry 14 . Volunteers meet criterion dependence substance nicotine . 15 . Participants body mass index 18 35 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>nicotine absorption</keyword>
</DOC>